flanders.bio is the cluster organisation empowering a life sciences driven network economy

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

CMAST is stepping into a strategic partnership with FlandersBio as of April 1st, 2017

CMAST is stepping into a strategic partnership with FlandersBio as of April 1st, 2017.
Through this partnership with FlandersBio, CMAST underlines its engagement of enabling Life Science Innovation in general and in Flanders in particular.

argenx announces results of Annual General Meeting 2017

argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CEST.

MDxHealth and Exact Sciences Sign Collaboration Agreement

MDxHealth SA (Euronext: MDXH.BR) today announced that it has signed a five-year agreement with Exact Sciences Corp. (Nasdaq: EXAS) for collaboration in the growing field of epigenetics and molecular diagnostics.

Biocartis Group NV: Biocartis Q1 2017 Business Update

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the first quarter of 2017, selected post period events and an outlook for the remainder of the year.

Aratana Therapeutics Provides Update on ENTYCE®

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced that it recently met with the U.S. Food and Drug Administration Center for Veterinary Medicine (CVM) regarding the proposed manufacturing transfer of ENTYCE® (capromorelin oral solution).

flanders.bio events

Alternate Text

17/05/2017 - State of the Union 2017

The evening before the annual Knowledge for Growth Conference we are organising the 3rd edition of our State of the Union; a moment to announce new developments and initiatives in the Flemish life sciences cluster and how we position ourselves vis-a-vis the European landscape. After several inspiring talks, there will be plenty of networking opportunities, accompanied by fine food and drinks. 

Strategic Partners